Nature Reviews Drug Discovery
Academic journal
From Wikipedia, the free encyclopedia
Nature Reviews Drug Discovery is a monthly peer-reviewed review journal published by Nature Portfolio. It was established in 2002[1] and covers drug discovery and development. The editor-in-chief is Peter Kirkpatrick.[2] According to the Journal Citation Reports, the journal has a 2021 impact factor of 112.288, ranking it 1st out of 158 journals in the category "Biotechnology & Applied Microbiology"[3] and 1st out of 279 journals in the category "Pharmacology & Pharmacy".[4]
| |
| Discipline | Pharmacology, Biotechnology |
|---|---|
| Language | English |
| Edited by | Peter Kirkpatrick |
| Publication details | |
| History | 2002–present |
| Publisher | |
| Frequency | Monthly |
| 101.8 (2024) | |
| Standard abbreviations | |
| ISO 4 | Nat. Rev. Drug Discov. |
| Indexing | |
| CODEN | NRDDAG |
| ISSN | 1474-1776 (print) 1474-1784 (web) |
| LCCN | 2002243044 |
| OCLC no. | 427380493 |
| Links | |
Reviews are commissioned to specialists and supplemented with glossary explanations for non-specialist readers and illustrated with figures drawn by Nature's in-house art editors. Besides reviews, the journal publishes analysis articles based on existing datasets (e.g. metaanalysis), progress articles that focus on outstanding issues, and perspective articles—typically opinions or historical pieces.[5]
